Company intelligence / Profile preview

Ionpath, Inc.

Menlo Park, California, United Statesionpath.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Ionpath was a pioneer in high-definition spatial proteomics, offering the MIBI™ platform for highly multiplexed protein imaging at subcellular resolution. The company shifted from selling instruments to providing spatial proteomics as a service. Their technology enabled deep phenotypic profiling of tissue microenvironments for translational and clinical researchers in fields such as immuno-oncology, immunology, neuroscience, and infectious diseases. As of early/mid 2024 or before, the company ceased operations.

Therapeutic areas: OncologyImmunologyNeurologyInfectious Diseases
Industry: Protein Biomarker Diagnostics

Partnerships

Thermo Fisher Scientific – strategic investment partnership to accelerate development and commercialization of MIBI technology.

Beyond the preview

Go deeper on Ionpath, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ionpath, Inc..

Explore the full profile